SCHEMBL15840688

SCHEMBL15840688

CCc1ccc2nc(Nc3nc(-c4cccc(OC)c4)cc(=O)[nH]3)nc(C)c2c1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.67
ALDH1A1 P00352 10/20 0.67
KMT2A Q03164 4/20 0.67
RAB9A P51151 4/20 0.67
CYP1A2 P05177 2/20 0.67
CYP3A4 P08684 2/20 0.67
CYP2C9 P11712 2/20 0.67
CYP2C19 P33261 2/20 0.67
MEN1 O00255 2/20 0.67
POLB P06746 2/20 0.67
NPC1 O15118 2/20 0.67
HTT P42858 2/20 0.67
ALPL P05186 1/20 0.67
SMN1; SMN2 Q16637 1/20 0.67
MITF O75030 1/20 0.67
PAX8 Q06710 1/20 0.67
TDP1 Q9NUW8 1/20 0.67
LMNA P02545 4/20 0.61
HSD17B10 Q99714 2/20 0.59
MAPK1 P28482 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23657888 0.82 MAPT (0.67) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840712 0.81 MAPT (0.64) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840596 0.80 MAPT (0.63) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840590 0.74 MAPK1 (0.75) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840817 0.72 MAPK1 (0.70) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL12473146 0.72 MAPT (0.85) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840609 0.71 STAT3 (0.74) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL15840749 0.70 MAPK1 (0.66) MAPTALDH1A1KMT2ARAB9ACYP1A2
SCHEMBL12656664 0.70 SMN1; SMN2 (0.68) MAPTALDH1A1KMT2AMEN1HTT
SCHEMBL6470208 0.70 AURKA (0.79) MAPTALDH1A1KMT2ARAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT Errico, Joseph P. (US) 2014-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140179681-A1 METHODS AND COMPOSITIONS OF TARGETED DRUG DEVELOPMENT EGFR, ERBB2, ERBB3 MAPT 1076/4885ALDH1A1 4348/4885KMT2A 3667/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.